Pfizer, patents and political quagmires

Shahan Islam said his enforcement efforts against generic producers often lead to counterarguments surrounding the price of Pfizer’s drugs and accusations that the company does not provide sufficient access to medicine for poorer people.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

Explainer: ARIPO’s role in Plant Variety Protection

15 July 2025 Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.

Africa

Commercialising genomic tech in Nigeria

29 April 2025 Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.

Africa

J&J pledges not to enforce TB patents in certain countries

3 October 2023 Non-profit hails move but urges other big pharma companies to follow suit | To avoid litigation, manufacturers must ensure generic versions are of good quality, medically acceptable, and are used only in the selected low-and middle-income countries.

More features

Litigator from Brown Rudnick moves firms to chair practice

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

Pfizer, patents and political quagmires

More on this story

Editor's picks

Editor's picks

More features